| Politician | Action | Description | Traded |
|---|---|---|---|
| Sell | REGENERON PHARMACEUTICAL INC | Sep 4, 2026 | |
| Sell | REGENERON PHARMACEUTICAL INC | Jun 16, 2026 | |
| Buy | REGENERON PHARMACEUTICAL INC | Jun 2, 2026 | |
| Sell | Regeneron Pharmaceuticals, I | May 15, 2026 | |
| Buy | Regeneron Pharmaceuticals, I | Mar 27, 2026 | |
| Buy | Regeneron Pharmaceuticals, I | Feb 12, 2026 | |
| Sell | REGENERON PHARMACEUTICALS IN | Feb 5, 2026 | |
| Buy | REGAL BIOMOON CORP CMN | Jan 31, 2026 | |
| Buy | REGENERON PHARMACEUTICALS IN | Jan 29, 2026 | |
| Buy | REGENERON PHARMACEUTICALS | Jan 29, 2026 |
This page tracks congressional stock trading activity in Regeneron Pharmaceuticals, Inc. (REGN) in the Healthcare sector. Disclosed Capitol has indexed 233 disclosed congressional trades involving REGN. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of October 2026 — Disclosed Capitol has tracked 233 disclosed congressional trades in Regeneron Pharmaceuticals, Inc. (REGN) — 123:101 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Sep 4, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Jun 16, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Jun 2, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| May 15, 2026 | Gilbert Cisneros | D | Sell | $1,001 - $15,000 |
| Mar 27, 2026 | Alan Armstrong | R | Buy | $1,001 - $15,000 |
| Feb 12, 2026 | Julia Letlow | R | Buy | $1,001 - $15,000 |
| Feb 5, 2026 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Jan 31, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jan 29, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jan 29, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
Across the 233 disclosed congressional trades in Regeneron Pharmaceuticals, Inc. (REGN), members of Congress have reported 101 buys and 123 sells. The average 30-day alpha vs. the S&P 500 is -0.95%.
As of October 2026, corporate insiders at Regeneron Pharmaceuticals, Inc. have filed 119 SEC Form 4 transactions in REGN over the past 12 months — including 71 sells worth $10.8M.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $5K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $26K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $12K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $18K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $11K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $56K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $21K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $42K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $19K |
| 2026-10-14 | MURPHY ANDREW J — Co-Chief Scientific Officer | Sale | $167K |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
As of September 2026, Regeneron Pharmaceuticals, Inc. has 31 federal contract award records on file from USAspending.gov — most recently $277.8M from the Department of Health and Human Services on 2026-09-25.
| Award date | Agency | Amount |
|---|---|---|
| 2026-09-25 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | $277.8M |
| 2026-09-16 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | -$766K |
| 2026-07-30 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | $2.7M |
| 2026-03-19 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | -$338K |
| 2025-08-08 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | -$331.7M |
| 2024-07-23 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | -$1.4M |
| 2023-08-21 | Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response | $326.5M |
| 2021-11-24 | Department of Veterans Affairs | $494K |
| 2021-09-14 | Department of Defense · Department of the Army | $2.94B |
| 2021-09-08 | Department of Veterans Affairs | $148K |
Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.
For fiscal year 2025, Regeneron Pharmaceuticals, Inc. reported revenue of $14.34B and net income of $4.50B, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $7.90B, net income $2.02B.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.